Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx Corp. (Nasdaq: OPRX) has announced the launch of a new health app by True™ Women’s Health, leveraging its RMDY digital health tools. The app aims to deliver virtual care and patient support, facilitating nationwide treatment during the COVID-19 pandemic. Dr. Diana Bitner highlighted its role in managing menopause, a key health concern for women. The app features educational resources, tracking, and telehealth consultations, promoting patient engagement. OptimizeRx’s tools are recognized for enhancing adherence in multiple health management areas, thus contributing to improved health outcomes.
OptimizeRx Corp. (NASDAQ: OPRX) announced that its Chief Commercial Officer, Steve Silvestro, received the 2020 PM360 ELITE 100 Award, recognizing his leadership in the healthcare sector. This prestigious award celebrates influential figures in healthcare, especially during the ongoing challenges posed by the COVID-19 pandemic. Silvestro was distinguished for his transformational leadership, enhancing organizational change and driving the growth of OptimizeRx's digital health platform. The award reflects his commitment to improving healthcare outcomes for stakeholders.
OptimizeRx Corp. (Nasdaq: OPRX) will participate in the Bank of America Merrill Lynch Health Care conference from May 12-14, 2020. CEO William Febbo is set to present on May 13 at 3:00 p.m. ET, discussing the company's record Q1 results, its extensive client base including the top 20 pharmaceutical companies, and its role in improving health outcomes via its digital health network, which reaches 60% of the U.S. ambulatory market. The event is exclusive to institutional clients and will feature opportunities for one-on-one meetings.
OptimizeRx Corp. (Nasdaq: OPRX) reported a remarkable 46% revenue increase for Q1 2020, reaching a record $7.6 million. Gross profit also rose by 20% to $4.3 million, though gross margin declined to 57.3% due to a favorable product mix last year. Operating expenses surged to $6.6 million, leading to a net loss of $2.2 million ($0.15 per share). The company is transitioning to a recurring revenue model with significant enterprise engagements. Cash reserves stood at $15.2 million. Management remains optimistic about growth amid increasing demand for digital health solutions.